MoonLake's Psoriatic Arthritis Drug Hits Endpoints, But Stock Drops 6%
MLTX has more than doubled off its 52-week low of $5.95 on elevated volume (2.4× avg).
Summary
Sonelokimab met all primary and secondary endpoints in the Phase 3 IZAR-1 trial for psoriatic arthritis, with a 42.1% ACR50 response. Despite the positive data, shares fell over 6%, suggesting the market may have expected even stronger results or is concerned about competitive positioning. This follows the earlier Dow Jones report of the trial success, but the sell-off is a new development. The company ended Q2 with $537 million in cash, funding operations into mid-2028. Full 52-week data is expected in H1 2027, and the companion IZAR-2 trial in TNF-refractory patients is enrolling with completion expected in Q3 2026.
At the time of this announcement, MLTX was trading at $17.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $5.95 to $62.75. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Benzinga.